ESALY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (31 Jan 2023 @ 02:29):

Stats
आज की मात्रा	331 859
औसत मात्रा	30 263.00
बाजार मूल्य	17.64B
EPS	$31.81 ( 2022-12-30 )
Last Dividend	$0.570 ( 2022-09-28 )
Next Dividend	$0 ( N/A )
P/E	20.54
ATR14	$2.32 (3.77%)

मात्रा सहसंबंध

लंबा: 0.00 (neutral)

छोटा: -0.91 (very strong negative)

Signal:(39.154) Neutral

Eisai Co., Ltd. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Eisai Co., Ltd. सहसंबंध - मुद्रा/वस्त्र

0.73
( moderate )

0.33
( neutral )

-0.64
( weak negative )

0.76
( moderate )

-0.37
( neutral )

0.30
( neutral )

Eisai Co., Ltd. वित्तीय

Annual	2022
राजस्व:	$756.23B
सकल लाभ:	$581.40B (76.88 %)
EPS:	$159.44

FY	2022
राजस्व:	$756.23B
सकल लाभ:	$581.40B (76.88 %)
EPS:	$159.44

FY	2021
राजस्व:	$645.94B
सकल लाभ:	$484.63B (75.03 %)
EPS:	$146.95

FY	2020
राजस्व:	$695.62B
सकल लाभ:	$519.93B (74.74 %)
EPS:	$425.01

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.570 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.34 - average (45.15%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.110	2010-03-28
Last Dividend	$0.570	2022-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	26	--
Total Paid Out	$20.43	--
Avg. Dividend % Per Year	0.00%	--
Score	1.89	--
Div. Sustainability Score	5.34
Div.Growth Potential Score	0
Div. Directional Score	2.09	--

Next Divdend (Est)
(2024-07-02)

$0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

1.89

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PUODY	Ex Dividend Knight	2023-06-21	Annually	0.00%
ENBFF	Ex Dividend Knight	2023-08-14	Quarterly	0.00%
VNRFY	Ex Dividend Junior	2023-05-30	Annually	0.00%
KPLUY	Ex Dividend Junior	2023-05-11	Annually	0.00%
CCFC	Ex Dividend Junior	2023-05-12	Quarterly	0.00%
SCRYY	Ex Dividend Junior	2023-05-25	Annually	0.00%
FQVLF	Ex Dividend Junior	2023-08-25	Annually	0.00%
MONDY	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
CNBZ	Ex Dividend Junior	2023-07-26	Semi-Annually	0.00%
STWRY	Ex Dividend Junior	2023-05-19	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0358	1.500	9.28	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0104	1.200	9.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0162	1.500	-0.931	-1.397	[0.1 - 1]
payoutRatioTTM	1.772	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.945	0.800	5.27	4.22	[1 - 3]
quickRatioTTM	0.858	0.800	9.66	7.73	[0.8 - 2.5]
cashRatioTTM	0.854	1.500	6.36	9.55	[0.2 - 2]
debtRatioTTM	0.120	-1.500	8.00	-10.00	[0 - 0.6]
interestCoverageTTM	7.68	1.000	8.27	8.27	[3 - 30]
operatingCashFlowPerShareTTM	-103.59	2.00	-10.00	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-145.33	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.194	-1.500	9.22	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.746	1.000	0.897	0.897	[0.2 - 0.8]
operatingProfitMarginTTM	0.0226	1.000	-1.547	-1.547	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.198	1.000	-2.21	-2.21	[0.2 - 2]
assetTurnoverTTM	0.289	0.800	-1.405	-1.124	[0.5 - 2]
Total Score				5.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	208.40	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0162	2.50	-0.599	-1.397	[0.1 - 1.5]
freeCashFlowPerShareTTM	-145.33	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-103.59	2.00	-10.00	-10.00	[0 - 30]
payoutRatioTTM	1.772	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-0.0478	1.500	-3.65	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0821	1.000	-4.55	0	[0.1 - 0.5]
Total Score				-1.153

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.